iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Analysts at Wedbush issued their FY2027 earnings per share estimates for iTeos Therapeutics in a research report issued to clients and investors on Wednesday, March 15th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($6.43) for the year. Wedbush currently has a “Outperform” rating and a $33.00 price objective on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($4.30) per share.
Several other equities analysts have also issued reports on the company. JPMorgan Chase & Co. dropped their price objective on iTeos Therapeutics from $34.00 to $32.00 and set an “overweight” rating on the stock in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $54.00 price target on shares of iTeos Therapeutics in a report on Friday.
iTeos Therapeutics Stock Performance
Hedge Funds Weigh In On iTeos Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd purchased a new position in shares of iTeos Therapeutics during the first quarter worth about $67,000. Quantbot Technologies LP acquired a new stake in iTeos Therapeutics in the second quarter valued at about $69,000. Mutual of America Capital Management LLC lifted its position in iTeos Therapeutics by 17.4% in the second quarter. Mutual of America Capital Management LLC now owns 3,402 shares of the company’s stock valued at $70,000 after purchasing an additional 505 shares during the period. Ensign Peak Advisors Inc acquired a new stake in iTeos Therapeutics in the first quarter valued at about $73,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in iTeos Therapeutics in the third quarter valued at about $117,000.
About iTeos Therapeutics
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.